Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease.

PLoS One 2019 11;14(4):e0215004. Epub 2019 Apr 11.

Center for Clinical Pharmacology, Washington University School of Medicine and St. Louis College of Pharmacy, St. Louis, MO, United States of America.

Alzheimer's disease currently lacks treatment options that effectively reverse the biological/anatomical pathology and cognitive deficits associated with the disease. Loss of function of the nuclear receptor REV-ERB is associated with reduced cognitive function in mouse models. The effect of enhanced REV-ERB activity on cognitive function has not been examined. In this study, we tested the hypothesis that enhanced REV-ERB function may enhance cognitive function in a model of Alzheimer's disease. We utilized the REV-ERB agonist SR9009 to pharmacologically activate the activity of REV-ERB in the SAMP8 mouse model of Alzheimer's disease. SR9009 reversed cognitive dysfunction of an aged SAMP8 mouse in several behavioral assays including novel object recognition, T-maze foot shock avoidance, and lever press operant conditioning task assessments. SR9009 treatment reduced amyloid-β 1-40 and 1-42 levels in the cortex, which is consistent with improved cognitive function. Furthermore, SR9009 treatment led to increased hippocampal PSD-95, cortical synaptophysin expression and the number of synapses suggesting improvement in synaptic function. We conclude that REV-ERB is a potential target for treatment of Alzheimer's disease.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215004PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459530PMC
April 2019

Publication Analysis

Top Keywords

alzheimer's disease
20
cognitive function
16
model alzheimer's
12
sr9009 treatment
8
receptor rev-erb
8
mouse model
8
cognitive deficits
8
samp8 mouse
8
enhanced rev-erb
8
nuclear receptor
8
cognitive
7
rev-erb
7
function
7
disease
6
alzheimer's
5
reduced amyloid-β
4
sr9009 pharmacologically
4
1-40 1-42
4
amyloid-β 1-40
4
sr9009
4

Similar Publications